Subgroup analysis of efficacy and safety of fruquintinib plus paclitaxel versus paclitaxel in gastroesophageal junction adenocarcinoma patients from FRUTIGA: A randomized phase 3 clinical trial in second-line treatment of gastric/gastroesophageal junction adenocarcinoma.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Tianshu Liu, Rui-Hua Xu, Feng Wang, Lin Shen, Weijian Guo, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yueyin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Panfeng Tan, Michael Shi
Institutions: Fudan University, Zhongshan Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, Tongji University, Shanghai East Hospital, China Pharmaceutical University, Third Affiliated Hospital of Harbin Medical University, Second Affiliated Hospital of Anhui Medical University, Henan Cancer Hospital, Anhui Provincial Hospital, Jiangsu Province Hospital, First Affiliated Hospital of Bengbu Medical College, Jilin Province Tumor Hospital, First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Sir Run Run Shaw Hospital, Zhejiang University, HUTCHMED (China) Limited (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410811489